Oncology ESMO25: On allosteric modulation in oncology, with Michael L... At ESMO 2025, pharmaphorum had the pleasure of speaking with Michael Lahn, Chief Medical Officer at iOnctura.
Oncology Realising the potential of autotaxin inhibition in cancer Tackling the fibroblast cells that form scar tissue around tumours takes down a barrier that prevents or inhibits the effect of many therapies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
